242 participants
SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2023-10-12
- Start Date:
- 2023-05-11
- Completion:
- 2028-02-01
Conditions
- Non-small Cell Lung Cancer
Interventions
- DRUG
No Results Yet